Ease of Use, Ease of Learning, and Convenience of the CagriSema Dual-Chamber Pen: Results From a Usability Study in Adults With Overweight, Obesity, or Type 2 Diabetes
This study evaluated the usability of the CagriSema dual-chamber pen, a single-dose, single-use, pre-filled autoinjector for once-weekly subcutaneous administration of a fixed-dose combination of cagrilintide and semaglutide. Adults with overweight/obesity (n = 85) or type 2 diabetes (n = 65) performed simulated injections after standardized training. Endpoints included injection completeness, task durations, and user feedback via the Injection Device Experience and Acceptability-Ease of Use and Convenience Questionnaire (IDEA-ECQ; content validity supported by cognitive interviews, n = 50). All but one participant completed the injection successfully. Median training time was 3 minutes, and time to prepare and inject was 15 seconds. Participants rated the device easy/very easy to use (100%), easy/very easy to learn (98.7%), and an injection with the pen convenient (99.3%). Results were consistent across populations and unaffected by prior device experience.
Authors
- Walter Gulisano (ORCID: https://orcid.org/0000-0002-3415-3924)
- E Hildebrand (ORCID: https://orcid.org/0000-0002-3519-1228)
- Riia Sustarsic (ORCID: https://orcid.org/0000-0001-8138-7363)
- Joshua Feinberg (ORCID: https://orcid.org/0000-0003-1975-9300)
- Thomas Sparre (ORCID: https://orcid.org/0000-0002-1441-0727)
- Gitte Ter-Borch
- Maya Gonczi
- Gina Legere-DeJohn
- Paul Brown
Institutions
- Novo Nordisk (Denmark) (DK)
- Novo Nordisk (United States) (US)
- Camber Collective (United States) (US)
Publication Details
- Journal
- Journal of Diabetes Science and Technology
- Published
- 2026-06-28
- DOI
- https://doi.org/10.1177/19322968261461530
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00